To view this email as a web page, go here.

To make sure you continue to receive this e-newsletter, please add info@iononline.com to your address book.

specialty-spotlight-hero

Visit FLT3AML-revealed.com to learn more.
Astellas
  Explore the key aspects of FLT3m+ AML  
  AML is a heterogeneous, hematologic disease that arises from the rapid expansion of myeloid blasts in the bone marrow and peripheral blood of adult patients.1 FLT3 is the most commonly identified gene mutation in AML.2,3  
 
 
Deepen your knowledge of FLT3m+ AML at
FLT3AML-revealed.com
 
AML=acute myeloid leukemia; FLT3=FMS-like tyrosine kinase 3; m+=mutation positive.
  References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia Version 1.2018. © National Comprehensive Cancer
Network, Inc. 2018. All rights reserved. Accessed 02-19-2018. To view the most recent and complete version of the guideline, go online to NCCN.org. 2. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-89. 3. Alvarado Y, Kantarjian HM, Luthra R, et al. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations. Cancer 2014;120(14):2142-9.
 
  © 2018 Astellas Pharma US, Inc. All rights reserved. 077-0067-PM. 4/18  
  Astellas and the flying star logo are trademarks of Astellas Pharma Inc.  
Astellas
 

This email was sent to: Amy.Gonsuron@iononline.com

This email was sent by: ION Solutions, An AmerisourceBergen Company
3101 Gaylord Parkway Frisco, TX 75034 USA


We respect your right to privacy - view our policy

This communication is intended to keep ION members current on late breaking events. It may contain confidential information such as pricing, rebate, and other discount arrangements being provided exclusively to ION members, and as such is intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, copying, distribution or other use of this material is strictly prohibited. In the event that you have received this material in error, or wish to opt-out of any future emails, please Go Here or notify the sender immediately via email or telephone at 866-565-1070 and destroy all copies. Thank you.